Cardiotoxicity Risk With Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity Matched Study of 1,790 Patients
American Journal of Hematology - United States
doi 10.1002/ajh.24599
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 17, 2017
Authors
Publisher
Wiley